Zhiqin Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhiqin Deng has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Guangyu Zhu
Department of Chemistry City University of Hong Kong Hong Kong SAR China
15 shared publications Shu Chen
Department of Chemistry, City University of Hong Kong, Hong Kong SAR, P. R. China
5 shared publicationsLianling Yu
Department of Chemistry Jinan University Guangzhou P. R. China
4 shared publicationsMan-Kit Tse
Department of Chemistry, City University of Hong Kong, 83 Tat Chee Avenue, Hong Kong SAR 999077, People's Republic of China
4 shared publications- Na Wang
College of Marine Science and Biological Engineering, Qingdao University of Science & Technology, Qingdao 266042, China
4 shared publications - Zhigang Wang
Nation-Regional Engineering Lab for Synthetic Biology of Medicine, International Cancer Center, School of Pharmacy, Shenzhen University Medical School, Shenzhen 518060, People's Republic of China
4 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (18) , e70492
Corrigendum to “Rational Design of Ruthenium Complexes Containing 2,6‐Bis(benzimidazolyl)pyridine Derivatives With Radiosensitization Activity by Enhancing p53 Activation”
- 15 September 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (18) , e70492
Open AccessCorrigendum to “Rational Design of Ruthenium Complexes Containing 2,6‐Bis(benzimidazolyl)pyridine Derivatives With Radiosensitization Activity by Enhancing p53 Activation”
- Open Access
- 9 September 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (37)
Hybridoma-inspired strategy crafts tailored multifunctional exosomes for precision therapy
Engineering functional exosomes represents a cutting-edge approach in biomedicine, holding the promise to transform targeted therapy. However, challenges such as achieving consistent modification and scalability have limited their wider adoption. Herein, we introduce a universal and effective strategy for engineering multifunctional exosomes through cell fusion. The hybrid-cell-derived exosomes could combine the functional properties of both parental cells and be readily produced by passaging. This method enables customization and large-scale production of exosomes with specific functionalities, potentially advancing precision therapies across a wide array of diseases. As demonstrated in Alzheimer’s disease (AD) models, exosomes derived from hybrid cells (HCs) (H/Exos) of mesenchymal stem cells (MSCs) and neutrophils efficiently targeted AD-affected areas via LFA-1/ICAM-1 and improved the cognition of AD mice. Beyond directly promoting neural repair and inhibiting inflammation, we surprisingly found that H/Exos increased microglia abundance, modulated microglia gene expression, enhanced the endocytic and lysosomal function, and promoted microglial phagocytic phenotypic differentiation to clear Aβ. This hybridoma-inspired strategy offers a versatile and practical way to engineer exosomes with desired therapeutic functions, representing a promising direction for personalized therapies.
- 9 September 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (37)
Open AccessHybridoma-inspired strategy crafts tailored multifunctional exosomes for precision therapy
Engineering functional exosomes represents a cutting-edge approach in biomedicine, holding the promise to transform targeted therapy. However, challenges such as achieving consistent modification and scalability have limited their wider adoption. Herein, we introduce a universal and effective strategy for engineering multifunctional exosomes through cell fusion. The hybrid-cell-derived exosomes could combine the functional properties of both parental cells and be readily produced by passaging. This method enables customization and large-scale production of exosomes with specific functionalities, potentially advancing precision therapies across a wide array of diseases. As demonstrated in Alzheimer’s disease (AD) models, exosomes derived from hybrid cells (HCs) (H/Exos) of mesenchymal stem cells (MSCs) and neutrophils efficiently targeted AD-affected areas via LFA-1/ICAM-1 and improved the cognition of AD mice. Beyond directly promoting neural repair and inhibiting inflammation, we surprisingly found that H/Exos increased microglia abundance, modulated microglia gene expression, enhanced the endocytic and lysosomal function, and promoted microglial phagocytic phenotypic differentiation to clear Aβ. This hybridoma-inspired strategy offers a versatile and practical way to engineer exosomes with desired therapeutic functions, representing a promising direction for personalized therapies.
- Open Access
- 3 October 2023
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 4 (12) , 1003-1013
Unlocking the potential of platinum drugs: organelle-targeted small-molecule platinum complexes for improved anticancer performance
This review offers a concise overview of platinum-based anticancer complexes targeting various organelles, aiming to overcome the limitations of existing platinum drugs.
- 3 October 2023
- Published by Royal Society of Chemistry (RSC) in RSC Chemical Biology
- Vol. 4 (12) , 1003-1013
Open AccessUnlocking the potential of platinum drugs: organelle-targeted small-molecule platinum complexes for improved anticancer performance
This review offers a concise overview of platinum-based anticancer complexes targeting various organelles, aiming to overcome the limitations of existing platinum drugs.
- Top Cited PapersOpen Access
- 23 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (25) , eadg5964
An ultrasound-activatable platinum prodrug for sono-sensitized chemotherapy
Despite the great success achieved by photoactivated chemotherapy, eradicating deep tumors using external sources with high tissue penetration depth remains a challenge. Here, we present cyaninplatin, a paradigm of Pt(IV) anticancer prodrug that can be activated by ultrasound in a precise and spatiotemporally controllable manner. Upon sono-activation, mitochondria-accumulated cyaninplatin exhibits strengthened mitochondrial DNA damage and cell killing efficiency, and the prodrug overcomes drug resistance as a consequence of combined effects from released Pt(II) chemotherapeutics, the depletion of intracellular reductants, and the burst of reactive oxygen species, which gives rise to a therapeutic approach, namely sono-sensitized chemotherapy (SSCT). Guided by high-resolution ultrasound, optical, and photoacoustic imaging modalities, cyaninplatin realizes the overall theranostics of tumors in vivo with superior efficacy and biosafety. This work highlights the practical utility of ultrasound to precisely activate Pt(IV) anticancer prodrugs for the eradication of deep tumor lesions and broadens the biomedical uses of Pt coordination complexes.
- 23 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (25) , eadg5964
Top Cited PapersOpen AccessAn ultrasound-activatable platinum prodrug for sono-sensitized chemotherapy
Despite the great success achieved by photoactivated chemotherapy, eradicating deep tumors using external sources with high tissue penetration depth remains a challenge. Here, we present cyaninplatin, a paradigm of Pt(IV) anticancer prodrug that can be activated by ultrasound in a precise and spatiotemporally controllable manner. Upon sono-activation, mitochondria-accumulated cyaninplatin exhibits strengthened mitochondrial DNA damage and cell killing efficiency, and the prodrug overcomes drug resistance as a consequence of combined effects from released Pt(II) chemotherapeutics, the depletion of intracellular reductants, and the burst of reactive oxygen species, which gives rise to a therapeutic approach, namely sono-sensitized chemotherapy (SSCT). Guided by high-resolution ultrasound, optical, and photoacoustic imaging modalities, cyaninplatin realizes the overall theranostics of tumors in vivo with superior efficacy and biosafety. This work highlights the practical utility of ultrasound to precisely activate Pt(IV) anticancer prodrugs for the eradication of deep tumor lesions and broadens the biomedical uses of Pt coordination complexes.
- Top Cited Papers
- 22 June 2023
- Published by Springer Nature in Nature Chemistry
- Vol. 15 (7) , 930-939
Near-infrared-activated anticancer platinum(IV) complexes directly photooxidize biomolecules in an oxygen-independent manner
Conventional light-driven cancer therapeutics require oxygen and visible light to indirectly damage biomolecules, limiting their efficacy in deep, hypoxic tumours. Here we report the use of near-infrared-activated small-molecule Pt(IV) photooxidants to directly oxidize intracellular biomolecules in an oxygen-independent manner, achieving controllable and effective elimination of cancer stem cells. These Pt(IV) complexes accumulate in the endoplasmic reticulum and show low toxicity in the dark. Upon irradiation, the resultant metal-enhanced photooxidation effect causes them to robustly photooxidize survival-related biomolecules, induce intense oxidative stress, disrupt intracellular pH (pHi) homeostasis and initiate nonclassical necrosis. In vivo experiments confirm that the lead photooxidant can effectively inhibit tumour growth, suppress metastasis and activate the immune system. Our study validates the concept of metal-enhanced photooxidation and the subsequent chemotherapeutic applications, supporting the development of such localized photooxidants to directly damage intracellular biomolecules and decrease pHi as a strategy for effective metal-based drugs.
- 22 June 2023
- Published by Springer Nature in Nature Chemistry
- Vol. 15 (7) , 930-939
Top Cited PapersNear-infrared-activated anticancer platinum(IV) complexes directly photooxidize biomolecules in an oxygen-independent manner
Conventional light-driven cancer therapeutics require oxygen and visible light to indirectly damage biomolecules, limiting their efficacy in deep, hypoxic tumours. Here we report the use of near-infrared-activated small-molecule Pt(IV) photooxidants to directly oxidize intracellular biomolecules in an oxygen-independent manner, achieving controllable and effective elimination of cancer stem cells. These Pt(IV) complexes accumulate in the endoplasmic reticulum and show low toxicity in the dark. Upon irradiation, the resultant metal-enhanced photooxidation effect causes them to robustly photooxidize survival-related biomolecules, induce intense oxidative stress, disrupt intracellular pH (pHi) homeostasis and initiate nonclassical necrosis. In vivo experiments confirm that the lead photooxidant can effectively inhibit tumour growth, suppress metastasis and activate the immune system. Our study validates the concept of metal-enhanced photooxidation and the subsequent chemotherapeutic applications, supporting the development of such localized photooxidants to directly damage intracellular biomolecules and decrease pHi as a strategy for effective metal-based drugs.
- 16 January 2023
- Published by Springer Nature in Nature Synthesis
- Vol. 2 (3) , 275-285
Enantioselective synthesis of tetraarylmethanes through meta-hydroxyl-directed benzylic substitution
- 16 January 2023
- Published by Springer Nature in Nature Synthesis
- Vol. 2 (3) , 275-285
Enantioselective synthesis of tetraarylmethanes through meta-hydroxyl-directed benzylic substitution
- Open Access
- 13 April 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 13 (19) , 5767-5773
Organocatalytic discrimination of non-directing aryl and heteroaryl groups: enantioselective synthesis of bioactive indole-containing triarylmethanes
Excellent enantiodiscrimination between aryl and heteroaryl groups without a directing group has been achieved with organocatalysis. The highly enantioenriched triarylmethane products exhibit anticancer and antiviral activities.
- 13 April 2022
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 13 (19) , 5767-5773
Open AccessOrganocatalytic discrimination of non-directing aryl and heteroaryl groups: enantioselective synthesis of bioactive indole-containing triarylmethanes
Excellent enantiodiscrimination between aryl and heteroaryl groups without a directing group has been achieved with organocatalysis. The highly enantioenriched triarylmethane products exhibit anticancer and antiviral activities.
- 13 December 2021
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 51 (3) , 885-897
The influence of different carbonate ligands on the hydrolytic stability and reduction of platinum(iv) prodrugs
Pt(IV) complexes bearing axial carbonate linkages have drawn much attention recently. A synthetic method behind this allows the hydroxyl group of bioactive ligands to be attached to the available hydroxyl group of Pt(IV) complexes, and the rapid release of free drugs is achieved after the reduction of carbonate-linked Pt(IV) complexes. Further understanding on the properties of Pt(IV) carbonates such as hydrolytic stability and reduction profiles, however, is hindered by limited research. Herein, six mono-carbonated Pt(IV) complexes in which the carbonate axial ligands possess various electron-withdrawing powers were synthesized, and the corresponding mono-carboxylated analogues were also prepared as references to highlight the different properties. The influence of the coordination environment towards the hydrolysis and reduction rate of Pt(IV) carbonates and carboxylates was explored. The mono-carbonated Pt(IV) complexes are both less stable and reduced faster than the corresponding mono-carboxylated ones. Moreover, the hydrolysis and reduction profiles are dependent not only on the electron-withdrawing ability of the carbonates but also on the nature of the opposite axial ligands. Besides, the exploration of the hydrolytic pathway for Pt(IV) carbonates suggests that the process proceeds by an attack of OH− on the carbonyl carbon, followed by elimination, which is different from that of Pt(IV) carboxylates. This study provides some information on the influence of axial carbonate ligands with different electron-withdrawing abilities on the properties of the Pt(IV) center, which may inspire new thoughts on the design of “multi-action” Pt(IV) prodrugs.
- 13 December 2021
- Published by Royal Society of Chemistry (RSC) in Dalton Transactions
- Vol. 51 (3) , 885-897
The influence of different carbonate ligands on the hydrolytic stability and reduction of platinum(iv) prodrugs
Pt(IV) complexes bearing axial carbonate linkages have drawn much attention recently. A synthetic method behind this allows the hydroxyl group of bioactive ligands to be attached to the available hydroxyl group of Pt(IV) complexes, and the rapid release of free drugs is achieved after the reduction of carbonate-linked Pt(IV) complexes. Further understanding on the properties of Pt(IV) carbonates such as hydrolytic stability and reduction profiles, however, is hindered by limited research. Herein, six mono-carbonated Pt(IV) complexes in which the carbonate axial ligands possess various electron-withdrawing powers were synthesized, and the corresponding mono-carboxylated analogues were also prepared as references to highlight the different properties. The influence of the coordination environment towards the hydrolysis and reduction rate of Pt(IV) carbonates and carboxylates was explored. The mono-carbonated Pt(IV) complexes are both less stable and reduced faster than the corresponding mono-carboxylated ones. Moreover, the hydrolysis and reduction profiles are dependent not only on the electron-withdrawing ability of the carbonates but also on the nature of the opposite axial ligands. Besides, the exploration of the hydrolytic pathway for Pt(IV) carbonates suggests that the process proceeds by an attack of OH− on the carbonyl carbon, followed by elimination, which is different from that of Pt(IV) carboxylates. This study provides some information on the influence of axial carbonate ligands with different electron-withdrawing abilities on the properties of the Pt(IV) center, which may inspire new thoughts on the design of “multi-action” Pt(IV) prodrugs.
- Open Access
- 6 October 2021
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 12 (43) , 14353-14362
An erythrocyte-delivered photoactivatable oxaliplatin nanoprodrug for enhanced antitumor efficacy and immune response
The outcome of conventional platinum (Pt)-based chemotherapy is limited by reduced circulation, failure to accumulate in the tumor, and dose-limiting toxicity arising from non-controllable activation. To address these limitations, we present an erythrocyte-delivered and near-infrared (NIR) photoactivatable PtIV nanoprodrug for advanced cancer treatment. Compared with small molecule PtIV prodrugs, this nanoprodrug exhibits significantly enhanced stability, prolonged circulation in the blood, and minimized side effects. The hitchhiking of the nanoprodrug on erythrocytes dramatically increases Pt accumulation in the tumor. Upon irradiation, the nanoprodrug releases oxaliplatin in a controllable manner, resulting in significant antitumor activity against breast tumors in vivo, as evidenced by the complete elimination of tumors from a single-dose injection. Additionally, this nanoprodrug is associated with remarkably enhanced immunopotentiation. Our study highlights an efficient strategy to overcome the shortcomings of traditional Pt-based chemotherapy via the erythrocyte-mediated delivery of an NIR-activatable nanoprodrug of oxaliplatin, a clinically used anticancer drug.
- 6 October 2021
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 12 (43) , 14353-14362
Open AccessAn erythrocyte-delivered photoactivatable oxaliplatin nanoprodrug for enhanced antitumor efficacy and immune response
The outcome of conventional platinum (Pt)-based chemotherapy is limited by reduced circulation, failure to accumulate in the tumor, and dose-limiting toxicity arising from non-controllable activation. To address these limitations, we present an erythrocyte-delivered and near-infrared (NIR) photoactivatable PtIV nanoprodrug for advanced cancer treatment. Compared with small molecule PtIV prodrugs, this nanoprodrug exhibits significantly enhanced stability, prolonged circulation in the blood, and minimized side effects. The hitchhiking of the nanoprodrug on erythrocytes dramatically increases Pt accumulation in the tumor. Upon irradiation, the nanoprodrug releases oxaliplatin in a controllable manner, resulting in significant antitumor activity against breast tumors in vivo, as evidenced by the complete elimination of tumors from a single-dose injection. Additionally, this nanoprodrug is associated with remarkably enhanced immunopotentiation. Our study highlights an efficient strategy to overcome the shortcomings of traditional Pt-based chemotherapy via the erythrocyte-mediated delivery of an NIR-activatable nanoprodrug of oxaliplatin, a clinically used anticancer drug.
- Open Access
- 1 April 2021
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 12 (19) , 6536-6542
An intramolecular photoswitch can significantly promote photoactivation of Pt(iv) prodrugs
The newly developed Pt(iv) prodrugs, rhodaplatins, contain an internal photoswitch and present up to 4.8 × 104-fold increased photoconversion efficiency compared to the conventional “photocatalyst plus Pt(iv) prodrug” photocatalysis platform.
- 1 April 2021
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 12 (19) , 6536-6542
Open AccessAn intramolecular photoswitch can significantly promote photoactivation of Pt(iv) prodrugs
The newly developed Pt(iv) prodrugs, rhodaplatins, contain an internal photoswitch and present up to 4.8 × 104-fold increased photoconversion efficiency compared to the conventional “photocatalyst plus Pt(iv) prodrug” photocatalysis platform.